Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, \>/= 18 years of age~* Histologically confirmed HER2-negative breast cancer~* Disease progression during or following first-line treatment with Avastin and chemotherapy for locally recurrent or metastatic breast cancer~* Avastin treatment in first-line setting must have been a minimum of 4 cycles (15 mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy~* ECOG performance status 0-2~* At least 28 days since prior radiation therapy or surgery and recovery from treatment~Exclusion Criteria:~* Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin for first-line treatment~* Active malignancy other than superficial basal cell and superficial squamous cell carcinoma of the skin, or in situ carcinoma of the cervix or breast within the last 5 years~* Inadequate renal function~* Clinically relevant cardio-vascular disease~* Known CNS disease except for treated brain metastases~* Chronic daily treatment with high-dose aspirin (\>325 mg/day) or clopidogrel (\>75 mg/day)~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).